Wikisage, the free encyclopedia of the second generation, is digital heritage
Amifampridine: Difference between revisions
Jump to navigation
Jump to search
(Created page with "Amifampridine phosphate was granted an Orphan Drug designation by the FDA for MG in September 2016, shortly after receiving a Refusal to File letter from the FDA for its submi...") |
No edit summary |
||
| Line 6: | Line 6: | ||
<references/> | <references/> | ||
{{Wikidata| | |||
{{Wikidata|Q411707}} | |||
Revision as of 00:13, 7 May 2019
Amifampridine phosphate was granted an Orphan Drug designation by the FDA for MG in September 2016, shortly after receiving a Refusal to File letter from the FDA for its submission for the treatment of congenital myasthenic syndromes and Lambert Eaton myasthenic syndrome (LEMS [1])[2]
Links
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-children-lambert-eaton-myasthenic-syndrome-rare-autoimmune-disorder Drug Trial Snapshot: Firdapse
